Frederic Bost

List of Publications by Year
in descending order

81 papers	10,249 citations	81900 39 h-index	66911 78 g-index
98 all docs	98 docs citations	98 times ranked	19287 citing authors

#	Article	IF	Citations
1	Low Doses of PFOA Promote Prostate and Breast Cancer Cells Growth through Different Pathways. International Journal of Molecular Sciences, 2022, 23, 7900.	4.1	5
2	Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies. Cell Death and Disease, 2021, 12, 64.	6.3	16
3	Hypoxia and hypoxiaâ€inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula. Journal of Physiology, 2021, 599, 2299-2321.	2.9	7
4	UBTD1 regulates ceramide balance and endolysosomal positioning to coordinate EGFR signaling. ELife, 2021, 10, .	6.0	7
5	The Adipose Tissue at the Crosstalk Between EDCs and Cancer Development. Frontiers in Endocrinology, 2021, 12, 691658.	3.5	14
6	TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 501-509.	1.9	18
7	Meeting report of the 4th biennial Metabolism and Cancer symposium. FEBS Journal, 2021, , .	4.7	0
8	Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics. PLoS Pathogens, 2020, 16, e1008660.	4.7	4
9	Evidences of a Direct Relationship between Cellular Fuel Supply and Ciliogenesis Regulated by Hypoxic VDAC1-Î”C. Cancers, 2020, 12, 3484.	3.7	9
10	Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. Nature Communications, 2020, 11, 4056.	12.8	96
11	Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-Î”C in clear cell Renal Cell Carcinoma patients. Theranostics, 2020, 10, 2696-2713.	10.0	12
12	Coâ€culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia. Journal of Cellular and Molecular Medicine, 2020, 24, 2931-2941.	3.6	7
13	An Adaptative Threshold Operator Taking Shape into Account: Application to Mitochondrial Network Segmentation. , 2019, , .		0
14	PGC1Î± Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness. Cancer Research, 2019, 79, 3268-3280.	0.9	27
15	Hypoxia protects against the cell death triggered by oxovanadiumâ€“galactomannan complexes in HepG2 cells. Cellular and Molecular Biology Letters, 2019, 24, 18.	7.0	8
16	Primary Cilium in Cancer Hallmarks. International Journal of Molecular Sciences, 2019, 20, 1336.	4.1	65
17	UBTD1 is a mechanoâ€regulator controlling cancer aggressiveness. EMBO Reports, 2019, 20, .	4.5	21
18	Editorial: Metformin: Beyond Diabetes. Frontiers in Endocrinology, 2019, 10, 851.	3.5	12

#	ARTICLE	IF	CITATIONS
19	TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC.. Journal of Clinical Oncology, 2019, 37, 5004-5004.	1.6	6
20	The metabolic modulator PGC-1Î± in cancer. American Journal of Cancer Research, 2019, 9, 198-211.	1.4	55
21	Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells. Breast Cancer Research and Treatment, 2018, 171, 581-591.	2.5	30
22	Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation. Scientific Reports, 2017, 7, 44779.	3.3	22
23	The energy disruptor metformin targets mitochondrial integrity via modification of calcium flux in cancer cells. Scientific Reports, 2017, 7, 5040.	3.3	47
24	Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight, 2017, 2, e87489.	5.0	304
25	Sirtuin 7: a new marker of aggressiveness in prostate cancer. Oncotarget, 2017, 8, 77309-77316.	1.8	24
26	Energy disruptors: rising stars in anticancer therapy?. Oncogenesis, 2016, 5, e188-e188.	4.9	91
27	Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics. Oncotarget, 2016, 7, 73270-73279.	1.8	1
28	Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation. Cancer & Metabolism, 2015, 3, 8.	5.0	36
29	Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 586-596.	4.1	38
30	Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget, 2015, 6, 15652-15661.	1.8	45
31	Metformin: A metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer Letters, 2014, 346, 188-196.	7.2	53
32	Metformin targets the GTPase Rac1 to inhibit prostate cancer cell migration. Cancer & Metabolism, 2014, 2, O24.	5.0	1
33	Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death. Cell Death and Differentiation, 2013, 20, 611-619.	11.2	137
34	The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Letters, 2013, 336, 114-126.	7.2	60
35	â€œDouble hitâ€•makes the difference. Cell Cycle, 2012, 11, 2979-2979.	2.6	1
36	Prevention of Mutagenesis: New Potential Mechanisms of Metformin Action in Neoplastic Cells. Cancer Prevention Research, 2012, 5, 503-506.	1.5	9

#	Article	IF	Citations
37	Metformin and cancer therapy. Current Opinion in Oncology, 2012, 24, 103-108.	2.4	77
38	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
39	Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1. Cancer Research, 2011, 71, 4366-4372.	0.9	545
40	Deficiency in the extracellular signal-regulated kinase 1 (ERK1) protects leptin-deficient mice from insulin resistance without affecting obesity. Diabetologia, 2011, 54, 180-189.	6.3	70
41	Insulin Induces REDD1 Expression through Hypoxia-inducible Factor 1 Activation in Adipocytes. Journal of Biological Chemistry, 2010, 285, 5157-5164.	3.4	47
42	The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy, 2010, 6, 670-671.	9.1	98
43	Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E1161-E1169.	3.5	126
44	Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells. Cancer Research, 2010, 70, 2465-2475.	0.9	465
45	Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?. Molecular Cancer Therapeutics, 2010, 9, 1092-1099.	4.1	444
46	Hypoxia Decreases Insulin Signaling Pathways in Adipocytes. Diabetes, 2009, 58, 95-103.	0.6	246
47	Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death. PLoS ONE, 2009, 4, e7889.	2.5	79
48	Abstract B95: Targeting cancer cell metabolism: The combination of metformin and 2â€deoxyglucose induces p53 dependent apoptosis in prostate cancer cells. , 2009, , .		0
49	The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008, 27, 3576-3586.	5.9	775
50	p38MAP Kinase activity is required for human primary adipocyte differentiation. FEBS Letters, 2007, 581, 5591-5596.	2.8	72
51	Concise Review: Regulation of Embryonic Stem Cell Lineage Commitment by Mitogen-Activated Protein Kinases. Stem Cells, 2007, 25, 1090-1095.	3.2	90
52	Role ofÂMAPKs inÂdevelopment andÂdifferentiation: lessons from knockout mice. Biochimie, 2006, 88, 1091-1098.	2.6	133
53	Inhibition of p38MAPK Increases Adipogenesis From Embryonic to Adult Stages. Diabetes, 2006, 55, 281-289.	0.6	160
54	p38 Mitogen-Activated Protein Kinase Activity Commits Embryonic Stem Cells to Either Neurogenesis or Cardiomyogenesis. Stem Cells, 2006, 24, 1399-1406.	3.2	94

#	Article	IF	Citations
55	A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells. Oncogene, 2005, 24, 6281-6291.	5.9	36
56	The Lac repressor provides a reversible gene expression system in undifferentiated and differentiated embryonic stem cell. Cellular and Molecular Life Sciences, 2005, 62, 1605-1612.	5.4	11
57	The Extracellular Signal-Regulated Kinase Isoform ERK1 Is Specifically Required for In Vitro and In Vivo Adipogenesis. Diabetes, 2005, 54, 402-411.	0.6	285
58	The role of MAPKs in adipocyte differentiation and obesity. Biochimie, 2005, 87, 51-56.	2.6	477
59	C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clinical Cancer Research, 2003, 9, 391-401.	7.0	94
60	Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. Biochemical Journal, 2002, 361, 621.	3.7	118
61	Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. Biochemical Journal, 2002, 361, 621-627.	3.7	163
62	The defective transforming phenotype of c-Jun Ala63/73 is rescued by mutation of the C-terminal phosphorylation site. Oncogene, 2001, 20, 7425-7429.	5.9	7
63	[24] Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family. Methods in Enzymology, 2000, 314, 342-362.	1.0	8
64	c-Jun N-terminal Kinase Is Essential for Growth of Human T98G Glioblastoma Cells. Journal of Biological Chemistry, 2000, 275, 24767-24775.	3.4	89
65	Differential Effect of Retinoic Acid on Growth Regulation by Phorbol Ester in Human Cancer Cell Lines. Journal of Biological Chemistry, 1999, 274, 29779-29785.	3.4	34
66	The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells. Molecular and Cellular Biology, 1999, 19, 1938-1949.	2.3	135
67	Inter-alpha-trypsin inhibitor proteoglycan family. A group of proteins binding and stabilizing the extracellular matrix. FEBS Journal, 1998, 252, 339-346.	0.2	193
68	Human Inter-Î±-Trypsin Inhibitor Heavy Chain H3 Gene. Journal of Biological Chemistry, 1998, 273, 26809-26819.	3.4	14
69	Molecular Determinants of AHPN (CD437)-Induced Growth Arrest and Apoptosis in Human Lung Cancer Cell Lines. Molecular and Cellular Biology, 1998, 18, 4719-4731.	2.3	165
70	Human inter-Î±-trypsin inhibitor heavy chain H3 gene. Genomic organization, promoter analysis, and gene linkage.. Journal of Biological Chemistry, 1998, 273, 30842.	3.4	4
71	The Jun Kinase/Stress-activated Protein Kinase Pathway Functions to Regulate DNA Repair and Inhibition of the Pathway Sensitizes Tumor Cells to Cisplatin. Journal of Biological Chemistry, 1997, 272, 14041-14044.	3.4	197
72	The JUN Kinase/Stress-activated Protein Kinase Pathway Is Required for Epidermal Growth Factor Stimulation of Growth of Human A549 Lung Carcinoma Cells. Journal of Biological Chemistry, 1997, 272, 33422-33429.	3.4	151

#	Article	IF	Citations
73	Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer. International Journal of Cancer, 1995, 64, 371-377.	5.1	40
74	Tandem orientation of the inter-Î±-trypsin inhibitor heavy chain H1 and H3 genes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1994, 1219, 551-554.	2.4	11
75	Human pre-alpha-trypsin inhibitor-precursor heavy chain cDNA and deduced amino-acid sequence. FEBS Journal, 1993, 212, 771-776.	0.2	32
76	Isolation and characterization of the human inter-alpha-trypsin inhibitor heavy-chain H1 gene. FEBS Journal, 1993, 218, 283-291.	0.2	16
77	Effect of Maternal Hyperglycemia on NaK ATPase Activity in Fetal Rat Kidney. Neonatology, 1993, 64, 304-309.	2.0	1
78	Human inter-Î±-trypsin inhibitor: Full-length cDNA sequence of the heavy chain H1. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1132, 114-118.	2.4	26
79	Organoids as a model to study the impact of EDCs on the prostate gland.. Endocrine Abstracts, 0, , .	0.0	0
80	Quantitative image based analysis of endocrine disruptor effects on mitochondria morphology-function in prostate cancer cells. Endocrine Abstracts, 0, , .	0.0	0
81	Low doses of persistent organic pollutants (PFOA and PCB153) increase the tumor aggressiveness of hormone-dependent cancer cells. Endocrine Abstracts, 0, , .	0.0	0